Aetion

Overview

Aetion is a regulatory-grade real-world evidence software and services platform, now operating as the RWE arm of Datavant after the July 2025 acquisition. It fits regulatory, medical, HEOR, payer / HTA, and post-market questions where study design, bias control, auditability, and source-data governance matter — not broad commercial data vending or sales dashboards.

For launch teams, the practical diligence question after the Datavant acquisition is what is already productized versus what depends on Datavant integration roadmap, implementation services, or separate source-data agreements. The platform itself (Aetion Evidence Platform with Discover, Activate, Substantiate, and Generate modules) is independent software; the data-connectivity story sits on top.

Platform Capability Model

The framework below standardizes how Rx Almanac evaluates data-technology-platforms capabilities, so buyers can compare vendors like-for-like while the readout column stays vendor-specific. For this table, Aetion is evaluated as regulatory-grade real-world evidence software and services platform, now operating as the RWE arm of Datavant after the July 2025 acquisition.

Capability	Buyer should compare	Aetion readout
Data aggregation and interoperability	Claims, EHR, CRM, pharmacy, provider, payer, and FHIR/API connectivity with normalization and identity resolution.	Core / diligence-critical. Aetion is data-agnostic software, but the value depends on the contracted source data and the Datavant connectivity model. Confirm which datasets are included, which require separate licensing, and how linkage is governed.
Commercial analytics and patient finding	Targeting, segmentation, patient finding, provider analytics, referral leakage, and opportunity sizing.	Major evidence work. AEP, Discover, Substantiate, and related services are built for regulated evidence questions rather than generic commercial dashboards.
Workflow automation and CRM integration	Case workflows, field workflows, CRM, task automation, document handling, and operational queue management.	Documented, validate adoption. Aetion Activate is the clearest public signal; buyers should confirm which user groups can work independently and where specialist support is still required.
Provider, payer, and pharmacy network connectivity	Network reach across HCPs, payers, pharmacies, labs, health systems, and transaction endpoints.	Not the main buying reason for Aetion; validate only if the SOW includes provider, payer, and pharmacy network connectivity.
AI, NLP, and unstructured data extraction	Conversation intelligence, document AI, NLP extraction, predictive models, and model monitoring.	Not the main buying reason for Aetion; validate only if the SOW includes ai, nlp, and unstructured data extraction.
Security, compliance, and governance	HIPAA, SOC2, data-use controls, auditability, consent, privacy, and regulated-workflow safeguards.	Major evidence governance. Aetion’s strongest fit is high-stakes evidence generation where the buyer needs defensible methods and governance. Automation workflow. AetionAI and Generate create upside, but buyers should evaluate guardrails, validation evidence, and when synthetic data is acceptable for the intended decision.
Reporting, dashboards, and data delivery	Dashboards, exports, APIs, scheduled reporting, and downstream feeds to analytics or operating teams.	Reporting layer. Clarify whether the deliverable is platform access, an executed study, a formal evidence package, or a mix of software and services.

Buyer Fit

• Where buyers should use it: Include Aetion when the manufacturer needs RWE that may support regulatory, safety, HEOR, payer, HTA, medical affairs, or post-market evidence decisions.
• Strongest users: Epidemiology, outcomes research, evidence generation, medical, market access, and analytics teams that need traceable methods and defensible study governance.
• Less direct fit: Pure provider targeting, quick commercial opportunity sizing, CRM workflow automation, or low-cost ad hoc analytics unless those needs are part of a broader evidence program.
• Commercial fit: Pricing is not publicly standardized, so assume an RFP-led scope with data rights, implementation support, user seats, governance, study volume, and deliverables defined in the agreement.
• Staffing diligence: Confirm source-data rights, Datavant integration maturity, workflow fit for non-technical users, AI controls, study reproducibility, and the handoff from platform output to payer / regulator-ready evidence.

Differentiators

• Evidence-first positioning: Aetion is built around RWE generation and causal inference, not a generic data warehouse or sales dashboard.
• Named platform modules: Discover, Activate, Substantiate, and Generate give buyers clearer diligence lanes across feasibility, data preparation, decision-grade studies, and synthetic patient data.
• Datavant adjacency: The 2025 acquisition can improve source-data discovery and linkage, but buyers should test what is live in production.
• AI-assisted workflows: AetionAI and Amazon Bedrock-enabled assistance may reduce manual study setup, provided governance and validation meet the buyer’s evidence standard.
• Enterprise deployment path: AWS Marketplace availability can simplify procurement and cloud deployment for organizations already standardized on AWS.

RFP Questions

• Which source-data assets are included, which require separate licensing, and who is responsible for rights, refresh cadence, and linkage?
• Which study types has Aetion executed in the relevant therapeutic area, endpoint, and geography?
• How does the platform document protocol decisions, cohort definitions, comparator logic, sensitivity analyses, and audit trails?
• Which workflows can non-technical HEOR or medical users run directly, and which still require epidemiology, data science, or Aetion services support?
• What AI-assisted features are enabled, what model controls are in place, and how are generated measures validated before use?
• How much of the Datavant-Aetion combined workflow is already productized versus handled through custom implementation?
• What deliverables will the manufacturer receive: platform access, study outputs, payer / HTA materials, publication support, or an integrated evidence package?

Recent Activity

• 2026-05 - Datavant positioning keeps Aetion as the RWE evidence arm while adding Datavant network and Sentinel 3.0 study-services context for source-data and study-governance diligence.

• July 2025: Datavant completed its acquisition of Aetion and integrated the business into Datavant’s life-sciences evidence ecosystem.

• May 2025: Aetion launched Activate, a collaborative application for real-world data preparation across code and no-code users.

• March 2025: Aetion made the Aetion Evidence Platform available in AWS Marketplace.

• February 2025: Aetion announced a strategic investment from NEC Orchestrating Future Fund tied to Japanese EHR-enabled drug-development use cases.

• February 2025: Aetion was named in CB Insights’ synthetic patient data market report, extending the public story around Generate and the Replica Analytics foundation.

• January 2025: Co-founder Jeremy Rassen returned as CEO and Christophe Berthoux joined as Executive Chair.

• June 2024: Aetion launched a Barcelona technology hub and appointed Ken Watson as Chief Technology Officer.